企業プロフィール
Amgen Inc. 株価・ニュース・カタリスト
- ティッカー:
- AMGN
- 取引所:
- NASDAQ
- セクター:
- Generics, Biopharma, Oncology, Immunotherapy
- 所在地:
- Thousand Oaks, California
株価パフォーマンス
419.38 USD (+1.00%)
終値
最終更新: 2026年8月17日
177B USD
時価総額
株価変動の要因
As of Aug 17, 2026, AMGN closed up 1.00% at $419.38. No new same-company headline was identified in the current news window.
企業概要
事業概要
Amgen develops, manufactures, and commercializes therapies across oncology, inflammation, bone health, cardiovascular disease, and rare disease. Marketed products such as Enbrel, Prolia, Repatha, Otezla, and Tepezza anchor the revenue base while the pipeline keeps catalysts in view.
所在地とセクター分類
Headquartered in Thousand Oaks, California and listed on NASDAQ, Amgen is a global biotechnology company with substantial U.S. and international revenue exposure. Its profile is shaped by scale, commercialization, and a broad therapeutic footprint.
ビジネスモデルの特徴
Amgen uses commercial cash flow to fund R&D and business development across both mature and newer franchises. Investors tend to watch launch execution, regulatory events, and portfolio refresh rather than pure clinical-stage binary risk.
バイオ業界での位置付け
Amgen is one of the best-known large-cap biotech names and usually trades with less single-asset dependence than smaller peers. It still moves on pipeline, regulatory, and label milestones, but its diversified base makes the story more durable.
今後のカタリスト
- Amgen’s near-term catalysts are TEPEZZA subcutaneous development, Repatha’s cardiovascular growth, and any MariTide update that could reset the obesity narrative. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.
最近のニュース
- 01
- 02
Management commentary keeps pipeline priorities in focus
- 03
Investors watch oncology and cardiometabolic launch cadence
- 04
Regulatory calendar keeps Amgen in the spotlight
- 05
Pipeline updates reinforce the commercial-stage narrative
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。